Beyond NMDA Receptors: A Narrative Review of Ketamine's Rapid and Multifaceted Mechanisms in Depression Treatment.

Ketamine shows rapid antidepressant effects primarily by blocking NMDA receptors, which reduces GABAergic inhibition and increases glutamate release. This activates AMPA receptors and downstream BDNF-TrkB and mTOR pathways, promoting synaptic growth and regeneration. Neuroimaging reveals changes in the Default Mode, Central Executive, and Salience networks—brain networks often disrupted in depression. The opioid system may play a permissive role in ketamine's effects, though ketamine is not a direct opioid agonist. Significant gaps remain in understanding its full mechanisms, safety, long-term efficacy, and how genetic factors like BDNF polymorphisms influence treatment response.

Study at a glance

Abstract

The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, its precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine's molecular actions. Ketamine primarily works by antagonizing NMDA receptors, reducing GABAergic inhibition, and increasing glutamate release. This enhanced glutamate activates AMPA receptors, triggering crucial downstream cascades, including BDNF-TrkB and mTOR pathways, promoting synaptic proliferation and regeneration. Moreover, neuroimaging studies have demonstrated alterations in brain networks involved in emotional regulation, including the Default Mode Network (DMN), Central Executive Network (CEN), and Salience Network (SN), which are frequently disrupted in depression. Despite the promising findings, the literature reveals significant inaccuracies and gaps in understanding the full scope of ketamine's therapeutic potential. For instance, ketamine engages with opioid receptors, insinuating a permissive role of the opioid system in amplifying ketamine's antidepressant effects, albeit ketamine does not operate as a direct opioid agonist. Further exploration is requisite to comprehensively ascertain its safety profile, long-term efficacy, and the impact of genetic determinants, such as BDNF polymorphisms, on treatment responsiveness.